Compare IONQ Inc (IONQ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Natera Inc. Common Stock — how do they compare? IONQ Inc trades at $30.83 (market cap $14.07B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.1× IONQ Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 34 Days and Natera Inc. Common Stock for 0 Days on average.
| IONQ | NTRA | |
|---|---|---|
Market Cap | $14.07B | $57.03B |
Volume | 23,412,195 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $72.41 | $425.64 |
52-Week Low | $26.59 | $179.42 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $12.01B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.73, down 4.25% today, with a bearish technical signal despite recent earnings beats. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a -553% net income margin. Analyst consensus is split with a $65.20 price target suggesting 88% upside potential, while technical indicators show oversold conditions with RSI at 26.86.
The stock presents high-risk, high-reward potential with Wall Street divided on its path to profitability. Key catalysts include quantum technology adoption and manufacturing scaling, while risks center on cash burn and competitive threats in the emerging quantum computing space.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
